CSPC Pharmaceutical Group Limited (Stock Code: 1093) announced that on 25 February 2026, its non-wholly owned subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (the “Vendor”) entered into an equity transfer agreement to sell a 30.07% stake in Beijing Guoxin Huijin Co., Ltd. (the “Target Company”) for RMB230.00 million. Following completion, the Vendor and the Group will no longer hold any equity interest in the Target Company.

According to the announcement, the consideration was based on an independent asset valuation that appraised the Target Company’s entire shareholders’ equity at RMB753.00 million as of 30 June 2025. The Target Company’s net asset value stood at RMB350.16 million as of 31 December 2025. CSPC Pharmaceutical Group Limited estimates a loss of around RMB15.00 million after transaction expenses. The deal is a connected transaction subject to shareholder approval of the Vendor by 30 June 2026, and it aims to optimize resource allocation and enable the Vendor to concentrate on its core businesses.